Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy

Phase 2

Completed

Conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Primary Myelofibrosis
Thrombocytopenia

Interventions: Drug: Eltrombopag Olamine

First Posted Date: 2011-09-05

Last Posted Date: 2023-09-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 21

Registration Number: NCT01428635

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Phase II Study of Cetuximab With or Without OSI-906 in Head and Neck Squamous Cell Carcinoma (HNSCC)

Phase 2

Withdrawn

Conditions: Head and Neck Cancer

Interventions: Drug: Cetuximab
Other: Placebo
Drug: OSI-906

First Posted Date: 2011-09-01

Last Posted Date: 2013-04-05

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT01427205

Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia

Phase 2

Active, not recruiting

Conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Acute Lymphoblastic Leukemia
Adult Acute Lymphoblastic Leukemia in Complete Remission
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Philadelphia Chromosome Positive
Untreated Adult Acute Lymphoblastic Leukemia

Interventions: Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Dexamethasone
Drug: Doxorubicin
Drug: Doxorubicin Hydrochloride
Other: Laboratory Biomarker Analysis
Drug: Methotrexate
Drug: Ponatinib
Drug: Ponatinib Hydrochloride
Drug: Prednisone
Biological: Rituximab
Drug: Vincristine
Drug: Vincristine Sulfate

First Posted Date: 2011-08-29

Last Posted Date: 2025-02-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 88

Registration Number: NCT01424982

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies

Phase 1

Completed

Conditions: Lymphoma

Interventions: Drug: Vorinostat
Drug: Gemcitabine
Drug: Busulfan
Drug: Melphalan
Procedure: Stem Cell Infusion
Drug: Rituximab
Drug: G-CSF
Drug: Palifermin
Drug: Dexamethasone acetate

First Posted Date: 2011-08-22

Last Posted Date: 2015-11-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 78

Registration Number: NCT01421173

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Temsirolimus In Phase 0

Early Phase 1

Completed

Conditions: Advanced Cancer

Interventions: Drug: Temsirolimus

First Posted Date: 2011-08-16

Last Posted Date: 2014-06-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 15

Registration Number: NCT01417065

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma

Phase 3

Completed

Conditions: Myeloma

Interventions: Drug: Busulfan
Drug: Melphalan
Other: Questionnaire
Drug: High Dose Melphalan
Drug: G-CSF
Procedure: Stem cell transplant

First Posted Date: 2011-08-10

Last Posted Date: 2020-04-21

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 205

Registration Number: NCT01413178

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

TEST: Registry for Endoscopic Head and Neck Surgery

Terminated

Conditions: Head and Neck Cancer

First Posted Date: 2011-08-09

Last Posted Date: 2013-06-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 2

Registration Number: NCT01412749

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Multimodal Therapy for the Treatment of Fatigue in Patients With Prostate Cancer Receiving Radiotherapy With Androgen Deprivation Therapy

Phase 2

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Other: Placebo
Drug: Methylphenidate
Behavioral: Counseling Sessions
Other: Sham Exercise
Other: Standardized Exercise Intervention Program
Other: Cognitive Behavioral Therapy (CBT)

First Posted Date: 2011-08-05

Last Posted Date: 2025-02-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 175

Registration Number: NCT01410942

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma

Phase 1

Terminated

Conditions: Melanoma

Interventions: Drug: Ipilimumab
Drug: Temozolomide
Drug: Cisplatin
Drug: Interferon Alfa-2b
Drug: Interleukin-2

First Posted Date: 2011-08-04

Last Posted Date: 2017-05-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 19

Registration Number: NCT01409174

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis

Phase 2

Active, not recruiting

Conditions: Metastatic Malignant Neoplasm in Lymph Node
Stage III Prostate Adenocarcinoma AJCC v7
Prostate Ductal Adenocarcinoma
Stage IV Prostate Adenocarcinoma AJCC v7

Interventions: Drug: Antiandrogen Therapy
Procedure: Radical Prostatectomy
Drug: Axitinib
Procedure: Regional Lymph Node Dissection

First Posted Date: 2011-08-04

Last Posted Date: 2025-06-19

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 73

Registration Number: NCT01409200

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy